Navigation Links
Farewell to TQT studies, new webinar hosted by Xtalks
Date:1/24/2013

Toronto, Canada (PRWEB) January 24, 2013

As requirements for cardiac studies tighten, the ICH-E14 guideline is essentially mandated for Thorough QT studies.

However, these studies are expensive and are usually performed late in Phase II or in Phase III, after many subjects have been exposed to an undefined repolarization risk. Also, by using the E-14 approach, a Sponsor will not learn of a drug’s QT liability until after a large expenditure of money and personnel effort.

A better assessment of QT liability can be achieved early in the drug development cycle, at lower cost to the Sponsor and lower risk to the subject. The strategy to achieve these goals will be discussed by the experts in this webinar.

For more information about this event or to register, visit: http://xtks.in/xto553-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10353974.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1

Related biology technology :

1. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
2. Webinar to Discuss Biosimilar Regulatory Guidelines in India and Emerging Markets
3. Live Webinar on Protection of Phase 1 Research Volunteers
4. Webinar on Clinical, Regulatory and Commercialization Strategies for Rare Diseases
5. The Veterinary Bioscience Institute Announces its January 2013 Webinar Schedule
6. The Veterinary Bioscience Institute Announces an Amazing Series of 41 Webinars for 2013
7. BioPharm Systems to Host Webinar on Self-service Account Management for Oracle Clinical, Remote Data Capture, and Thesaurus Management System
8. Best Practices, LLC Issues New Report and Webinar on Managing Healthcare Reform through Effective Engagement with the Government Ecosystem
9. Webinar Announcement: GenomeSpace: A New Solution for Integrating Genomic Analysis Tools
10. Northeastern University Nanomanufacturing Center Director Ahmed Busnaina to Present Webinar on “The Democratization of Manufacturing”
11. Clinovo Hosted the Fourth Silicon Valley BioTalks on June 6th, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... April 19, 2017 , ... ... (C. diff) infections through education and advocacy. Founded in 2010 in memory ... C. diff infection, the foundation has become the most-consulted source for patient-focused information ...
(Date:4/19/2017)... April 19, 2017  As a Bronze ... Heroin Summit ,  Proove® Biosciences, Inc. announces ... environmental, and lifestyle factors to accurately predict prescription ... of Southern California (USC), the Interventional Pain Institute ... publish results showing that Proove Opioid Risk® accurately ...
(Date:4/19/2017)... 19, 2017   Thermo Fisher Scientific Inc ... Procalcitonin MOnitoring SEpsis (MOSES) Study have been published ... Critical Care Medicine . Researchers from the study, ... Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis ... PCT (procalcitonin) assay to assess risk for 28 ...
(Date:4/18/2017)... (PRWEB) , ... April 18, 2017 , ... For a ... Associates, co-members in the VaxCorps vaccine consortium, were named one of the top two ... since the inception of this category; winning the award four times previously, and first ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):